Breast Cancer Microenvironment: Molecular Mechanisms and Therapeutic Targeting
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 152
Special Issue Editor
Interests: tumor microenvironment; breast cancer research; single cell/space transcriptome sequencing; machine learning
Special Issue Information
Dear Colleagues,
The breast cancer microenvironment (TME) plays a pivotal role in tumor progression, metastasis, and therapy resistance, yet its complex molecular crosstalk remains incompletely understood. This Special Issue seeks to highlight cutting-edge research elucidating the interplay between cancer cells and stromal components—fibroblasts, immune cells, endothelial cells, and extracellular matrix—within the breast TME. We welcome studies uncovering novel molecular drivers (e.g., ligand-receptor networks, epigenetic regulators, signaling pathways), mechanisms of microenvironment remodeling (e.g., ECM stiffness, metabolic reprogramming), and innovative therapeutic strategies targeting TME vulnerabilities (e.g., stromal-targeted therapies, immunotherapy combinations). Topics include, but are not limited to, the following:
- Fibroblast–cancer cell interactions in metastasis;
- Immune evasion and TME immunomodulation;
- Metabolic coupling between cancer and stromal cells;
- Biomarkers derived from TME features for prognosis/therapy guidance;
- Preclinical and clinical advances in TME-targeted interventions.
By integrating mechanistic insights with translational perspectives, this issue aims to accelerate progress toward precision therapies for breast cancer.
Dr. Yi Fang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- tumor microenvironment
- biomarkers
- therapeutic targeting
- tumor-stromal interactions
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
